Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
Braskem (BAK) Stock Slides -39% Over 30 Days on Restructuring Concerns

Braskem (BAK) Stock Slides -39% Over 30 Days on Restructuring Concerns

Key Takeaways

  • Braskem's ADRs have declined roughly 39% over the past 30 days, falling from about $1.54 to around $0.94 per share.
  • The sell-off extends a longer slide: BAK is down roughly 62% over the last three months from about $2.46 per share.
  • An unresolved, roughly $11 billion out-of-court debt restructuring is the central driver of the decline, with proposals still unaccepted.
  • Additional pressure came from an involuntary Chapter 11 filing against a financing subsidiary and a UBS downgrade to Sell.
  • Heavy proposed debt-to-equity conversions create substantial dilution risk for existing shareholders.
  • For additional data, explore Braskem's Price Targets, Earnings, and Forecast pages.
  • For AI-driven trading signals, explore Trending AI Robots.

A Quick Look at Braskem (BAK)'s Business

Braskem S.A. is Latin America's largest petrochemical company and one of the leading producers of thermoplastic resins in the Americas. Headquartered in Camaçari, Bahia, Brazil, the company manufactures polyethylene, polypropylene, and PVC, along with basic chemicals and fuels, serving packaging, automotive, construction, agriculture, and consumer goods industries. It is also a leading producer of biopolymers, including sugarcane-derived "green" polyethylene. Braskem operates across Brazil, the United States, Mexico, and Europe, and is the largest polypropylene producer in the U.S. and a leading polyethylene producer in Mexico. Investors follow the stock for its scale and cyclical exposure to global petrochemical spreads, though its heavy debt load and an environmental liability tied to salt-mining subsidence in Maceió, Alagoas, have dominated the investment narrative. I checked this using Tickeron's AI Screener to see how the stock compares to others in the industry.

Recent Price Action: 30 Days and the Quarter

Over the past 30 days, Braskem's ADRs have fallen roughly 39%, from a closing level near $1.54 in late September to about $0.94. The decline accelerated sharply in the latest sessions, with the shares moving below the level that had marked the prior 52-week low of around $1.40. The period featured several failed recovery attempts, as the stock briefly traded near $1.87 in mid-October before renewed restructuring headlines drove it lower.

The quarterly picture is even weaker. From roughly $2.46 per share in late July, BAK has dropped approximately 62% over the last three months. The stock reached a 52-week high near $5.40 within the past year, underscoring the scale of the multi-month repricing as debt concerns overwhelmed the cyclical petrochemical story.

Key Drivers Behind the Latest 30-Day Move

The dominant catalyst has been the company's roughly $11 billion debt restructuring. On October 24, 2026, Braskem disclosed the details of its updated restructuring proposals — including its own plan and a competing investor proposal — while confirming that no proposal had yet been accepted. Both plans contemplate a follow-on equity offering of about $2.25 billion and significant debt-to-equity conversions, mechanics that carry heavy dilution risk for existing shareholders. I also checked this using Tickeron's AI Trend Prediction Engine to gauge potential outcomes.

The process has also drawn legal escalation. On October 21, 2026, funds affiliated with Bracebridge Capital filed an involuntary Chapter 11 petition against Braskem America Finance Company, the issuer of roughly $587 million in notes due 2041. Separately, UBS downgraded Braskem to Sell from Neutral, cutting its ADR price target to $1.50 from $4, citing Chinese capacity additions that are expected to keep petrochemical spreads under pressure into the late 2020s. The shares also fell in a broad risk-off move among Brazilian equities ahead of a Federal Reserve interest-rate decision.

Broader Pressures Over the Past Quarter

The three-month decline reflects a convergence of structural pressures. In August 2026, Braskem initiated a Brazilian "extrajudicial recovery" (recuperação extrajudicial) to restructure roughly $11 billion of debt after years of financial strain. Negotiations with creditors and controlling shareholders — Petrobras and IG4 Capital — have repeatedly stalled over how much fresh capital shareholders must commit. UBS estimates total debt near $13.2 billion, or about 95% of total capital, with negative free cash flow of roughly $1.7 billion over the trailing 12 months. Weak global petrochemical spreads, the Maceió environmental liability, and ongoing losses have compounded the balance-sheet concerns, keeping the equity under sustained pressure.

What to Watch Going Forward

The path forward hinges primarily on the restructuring. A milestone under the negotiation framework was extended to October 30, 2026, and the parties face a November 22 deadline to reach an agreement. The key variables are the size of any debt write-down, the amount of fresh capital shareholders commit, and the extent of debt-to-equity conversion — all of which determine how much value, if any, existing shareholders retain. Investors should also monitor the involuntary Chapter 11 proceeding against Braskem America Finance Company, upcoming earnings and guidance, and petrochemical spread trends as Chinese capacity additions come online. Macroeconomic conditions, including U.S. interest-rate policy and the Brazilian real, add further sensitivity. These factors present meaningful uncertainty and should be weighed carefully; this article does not constitute investment advice.

Exploring AI Tools for Volatile Names

In my analysis of names like BAK, I often turn to Tickeron's AI Daily Buy/Sell Signals for a data-driven perspective on potential entry and exit points amid restructuring uncertainty. The platform aggregates signals across thousands of tickers, which helps put individual stock moves into broader context without replacing careful fundamental review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BAK

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BAK in -14.30% downward trend, falling for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BAK declined for three days, in 306 of 352 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In 61 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for BAK turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

BAK moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for BAK entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +5.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in 187 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

BAK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (-0.035) is slightly lower than the industry average of (1.147). P/E Ratio (-0.078) is within average values for comparable stocks, (3.243). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.769). BAK's Dividend Yield (2.475) is considerably higher than the industry average of (0.195). P/S Ratio (0.051) is also within normal values, averaging (0.578).

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

Notable companies

The most notable companies in this group are Dow (NYSE:DOW).

Industry description

The major diversified chemicals industry includes companies that produce a wide range of chemicals and industrial gases. The products are often used as raw materials in the manufacturing of various types of goods, including plastics, paints, carpets, and fixtures to name a few. Major companies making diversified chemicals include DuPont de Nemours Inc., Celanese Corporation, Celanese Corporation and Westlake Chemical Corporation.

Market Cap

The average market capitalization across the Chemicals: Major Diversified Industry is 2.83B. The market cap for tickers in the group ranges from 80.4K to 67.31B. SHECF holds the highest valuation in this group at 67.31B. The lowest valued company is DEVV at 80.4K.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Major Diversified Industry was -16%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -31%. GURE experienced the highest price growth at -2%, while TROX experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Major Diversified Industry was 43%. For the same stocks of the Industry, the average monthly volume growth was 5% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 52
Price Growth Rating: 62
SMR Rating: 84
Profit Risk Rating: 89
Seasonality Score: 5 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals and other related products

Industry ChemicalsMajorDiversified

Industry
Chemicals Specialty
Address
Rua Lemos Monteiro
Phone
+55 1135769531
Employees
8233
Web
https://www.braskem.com.br
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.